Literature DB >> 28707053

Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Hiroji Shinkawa1, Kiyoshi Hasegawa2, Junichi Arita1, Nobuhisa Akamatsu1, Junichi Kaneko1, Yoshihiro Sakamoto1, Norihiro Kokudo1.   

Abstract

BACKGROUND: Although achieving a sustained virological response (SVR) in hepatitis C virus (HCV) infection is recognized as improving liver function and reducing hepatocellular carcinoma (HCC) development, its impact on HCC recurrence is unclear. This study investigated how preoperative SVR achievement by interferon treatment affects HCC recurrence in patients undergoing hepatic resection.
METHODS: The study subjects were 521 patients with HCV infection who underwent initial and curative hepatic resection for HCC. To adjust for confounding factors between the SVR and non-SVR groups, propensity score-matching analysis was performed.
RESULTS: After propensity score matching, 45 of the 49 patients in the SVR group, and an equal number of the 472 patients in the non-SVR group, were matched. The two groups had similar distributions of clinicopathological characteristics. In the matched cohort, the 3-, 5-, and 7-year recurrence-free survival rates after surgery were 56, 45, and 37%, respectively, in the SVR group, and 34, 23, and 7.2%, respectively, in the non-SVR group (p = 0.033). Additionally, the 3-, 5-, and 7-year overall survival rates after surgery were 82, 80, and 75%, respectively, in the SVR group, and 78, 64, and 44%, respectively, in the non-SVR group (p = 0.065). The 1- and 2-year cumulative recurrence rates in the early phase showed no significant difference between the SVR and non-SVR groups (p = 0.27). however, the 3-, 5-, and 7-year cumulative recurrence rates in the late phase were 14, 32, and 43%, respectively, in the SVR group, and 33, 55, and 86%, respectively, in the non-SVR group (p = 0.037).
CONCLUSION: Achievement of SVR may reduce postoperative recurrence after hepatic resection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28707053     DOI: 10.1245/s10434-017-6008-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk.

Authors:  Feng Su; George N Ioannou
Journal:  Curr Hepatol Rep       Date:  2018-09-20

2.  Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status.

Authors:  Masaki Koda; Shogo Tanaka; Shigekazu Takemura; Hiroji Shinkawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Norifumi Kawada; Toshihiko Shibata; Shoji Kubo
Journal:  Liver Cancer       Date:  2018-03-13       Impact factor: 11.740

3.  Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.

Authors:  Hironori Ochi; Atsushi Hiraoka; Masashi Hirooka; Yohei Koizumi; Michiko Amano; Nobuaki Azemoto; Takao Watanabe; Osamu Yoshida; Yoshio Tokumoto; Toshie Mashiba; Tomoyuki Yokota; Masanori Abe; Kojiro Michitaka; Yoichi Hiasa; Kouji Joko
Journal:  J Gastroenterol       Date:  2020-12-05       Impact factor: 7.527

4.  Viral elimination is essential for improving surgical outcomes of hepatitis C virus-related hepatocellular carcinoma: Multicenter retrospective analysis.

Authors:  Masao Nakajima; Shogo Kobayashi; Hiroshi Wada; Akira Tomokuni; Hidenori Takahashi; Takehiro Noda; Hiroto Matsui; Satoshi Matsukuma; Shinsuke Kanekiyo; Yoshitaro Shindo; Yukio Tokumitsu; Yuki Nakagami; Nobuaki Suzuki; Shigeru Takeda; Masahiro Tanabe; Katsuyoshi Ito; Yoshinobu Hoshii; Hidetoshi Eguchi; Hiroaki Nagano
Journal:  Ann Gastroenterol Surg       Date:  2020-07-23

5.  AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.

Authors:  Takao Watanabe; Yoshio Tokumoto; Kouji Joko; Kojiro Michitaka; Norio Horiike; Yoshinori Tanaka; Fujimasa Tada; Yoshiyasu Kisaka; Seiji Nakanishi; Kazuhiko Yamauchi; Hironori Ochi; Atsushi Hiraoka; Sen Yagi; Atsushi Yukimoto; Masashi Hirooka; Masanori Abe; Yoichi Hiasa
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

6.  Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma.

Authors:  Wei Teng; Wen-Juei Jeng; Hwai-I Yang; Wei-Ting Chen; Yi-Chung Hsieh; Chien-Hao Huang; Chen-Chun Lin; Chun-Yen Lin; Shi-Ming Lin; I-Shyan Sheen
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.